Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert D'Haens

Showing results (171-180 of 269) with videos related to

Pageof 27
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 4, 2020
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's DiseasePeter Bossuyt, Erwin Dreesen, Jordi Rimola, et al.
Gut|April 25, 2012
Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegolXavier Hébuterne, Marc Lémann, Yoram Bouhnik, et al.
Journal of Crohn'S & Colitis|March 20, 2023
A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn's DiseaseMatthieu Allez, Bruce E Sands, Brian G Feagan, et al.
Inflammatory Bowel Diseases|April 25, 2024
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's DiseaseReena Khanna, Brian G Feagan, Guangyong Zou, et al.
United European Gastroenterology Journal|October 14, 2024
Cost-effectiveness and cost-utility of optimized mercaptopurine treatment versus placebo in ulcerative colitis patients: The randomized controlled OPTIC trialMark Löwenberg, Marit van Barreveld, Adriaan Volkers, et al.
United European Gastroenterology Journal|May 9, 2026
Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative ColitisAilsa Hart, Seyedehsan Navabi, Geert D'Haens, et al.
Gastroenterology|June 9, 2019
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's DiseaseMark Löwenberg, Severine Vermeire, Nahid Mostafavi, et al.
Alimentary Pharmacology & Therapeutics|July 26, 2024
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's diseaseStefan Schreiber, Raymond K Cross, Remo Panaccione, et al.
Inflammatory Bowel Diseases|February 28, 2020
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM StudyWalter Reinisch, Remo Panaccione, Peter Bossuyt, et al.
Journal of Crohn'S & Colitis|May 12, 2025
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitisGeert D'Haens, Silvio Danese, Remo Panaccione, et al.
Pageof 27

Showing results (171-180 of 269) with videos related to

Sort By:
Pageof 27
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 4, 2020
Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's DiseasePeter Bossuyt, Erwin Dreesen, Jordi Rimola, et al.
Gut|April 25, 2012
Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegolXavier Hébuterne, Marc Lémann, Yoram Bouhnik, et al.
Journal of Crohn'S & Colitis|March 20, 2023
A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn's DiseaseMatthieu Allez, Bruce E Sands, Brian G Feagan, et al.
Inflammatory Bowel Diseases|April 25, 2024
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's DiseaseReena Khanna, Brian G Feagan, Guangyong Zou, et al.
United European Gastroenterology Journal|October 14, 2024
Cost-effectiveness and cost-utility of optimized mercaptopurine treatment versus placebo in ulcerative colitis patients: The randomized controlled OPTIC trialMark Löwenberg, Marit van Barreveld, Adriaan Volkers, et al.
United European Gastroenterology Journal|May 9, 2026
Effect of Mirikizumab on Clinical and Endoscopic Outcomes Based on Prior Advanced Therapy Failure in Patients With Moderately to Severely Active Ulcerative ColitisAilsa Hart, Seyedehsan Navabi, Geert D'Haens, et al.
Gastroenterology|June 9, 2019
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's DiseaseMark Löwenberg, Severine Vermeire, Nahid Mostafavi, et al.
Alimentary Pharmacology & Therapeutics|July 26, 2024
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's diseaseStefan Schreiber, Raymond K Cross, Remo Panaccione, et al.
Inflammatory Bowel Diseases|February 28, 2020
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM StudyWalter Reinisch, Remo Panaccione, Peter Bossuyt, et al.
Journal of Crohn'S & Colitis|May 12, 2025
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitisGeert D'Haens, Silvio Danese, Remo Panaccione, et al.
Pageof 27